HB Wealth Management LLC Increases Stock Holdings in Moderna, Inc. (NASDAQ:MRNA)

HB Wealth Management LLC grew its holdings in Moderna, Inc. (NASDAQ:MRNA) by 31.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 3,850 shares of the company’s stock after acquiring an additional 919 shares during the quarter. HB Wealth Management LLC’s holdings in Moderna were worth $410,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the business. Caprock Group LLC raised its position in Moderna by 25.2% during the 1st quarter. Caprock Group LLC now owns 3,082 shares of the company’s stock worth $328,000 after buying an additional 621 shares during the last quarter. Perigon Wealth Management LLC purchased a new stake in shares of Moderna during the first quarter worth about $255,000. Commonwealth Equity Services LLC lifted its stake in Moderna by 0.5% in the 1st quarter. Commonwealth Equity Services LLC now owns 75,184 shares of the company’s stock valued at $8,012,000 after buying an additional 411 shares in the last quarter. Greenleaf Trust boosted its stake in shares of Moderna by 41.4% in the first quarter. Greenleaf Trust now owns 3,253 shares of the company’s stock worth $347,000 after acquiring an additional 953 shares during the last quarter. Finally, Principal Financial Group Inc. boosted its position in Moderna by 0.8% during the first quarter. Principal Financial Group Inc. now owns 363,905 shares of the company’s stock worth $38,778,000 after acquiring an additional 2,948 shares during the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Moderna Trading Up 1.4 %

Shares of MRNA stock traded up $1.65 during mid-day trading on Friday, reaching $117.60. The company’s stock had a trading volume of 1,549,244 shares, compared to its average volume of 4,159,395. The company’s 50 day simple moving average is $134.88 and its 200-day simple moving average is $112.67. The company has a quick ratio of 3.91, a current ratio of 4.03 and a debt-to-equity ratio of 0.04. Moderna, Inc. has a 12-month low of $62.55 and a 12-month high of $170.47. The firm has a market capitalization of $45.07 billion, a PE ratio of -7.43 and a beta of 1.66.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings data on Thursday, May 2nd. The company reported ($3.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.59) by $0.52. The firm had revenue of $167.00 million during the quarter, compared to analyst estimates of $93.26 million. Moderna had a negative return on equity of 20.10% and a negative net margin of 115.82%. Moderna’s quarterly revenue was down 91.0% on a year-over-year basis. During the same quarter last year, the firm earned $0.19 EPS. On average, research analysts predict that Moderna, Inc. will post -7.46 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently commented on the company. Jefferies Financial Group reiterated a “buy” rating and issued a $125.00 price objective on shares of Moderna in a report on Tuesday, April 9th. Evercore ISI reiterated an “in-line” rating and issued a $120.00 target price on shares of Moderna in a research note on Thursday, June 27th. Oppenheimer upped their price objective on Moderna from $163.00 to $179.00 and gave the stock an “outperform” rating in a report on Wednesday, June 12th. Needham & Company LLC reaffirmed a “hold” rating on shares of Moderna in a research note on Friday, June 28th. Finally, Canaccord Genuity Group lifted their target price on shares of Moderna from $91.00 to $106.00 and gave the stock a “hold” rating in a research report on Friday, May 3rd. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, Moderna has an average rating of “Hold” and an average target price of $134.02.

Insider Buying and Selling

In related news, Director Noubar Afeyan sold 202,832 shares of the business’s stock in a transaction that occurred on Tuesday, June 11th. The stock was sold at an average price of $148.34, for a total transaction of $30,088,098.88. Following the completion of the transaction, the director now owns 1,528,557 shares in the company, valued at approximately $226,746,145.38. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, CFO James M. Mock sold 705 shares of the company’s stock in a transaction on Monday, April 8th. The shares were sold at an average price of $101.93, for a total value of $71,860.65. Following the completion of the sale, the chief financial officer now directly owns 5,048 shares in the company, valued at $514,542.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Noubar Afeyan sold 202,832 shares of the firm’s stock in a transaction that occurred on Tuesday, June 11th. The shares were sold at an average price of $148.34, for a total value of $30,088,098.88. Following the completion of the sale, the director now directly owns 1,528,557 shares in the company, valued at approximately $226,746,145.38. The disclosure for this sale can be found here. Insiders have sold a total of 396,255 shares of company stock worth $54,593,731 over the last quarter. 15.20% of the stock is owned by company insiders.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.